Clene Inc. and its subsidiary, Clene Nanomedicine Inc. have presented clinical results from two long-term extension trials highlighting the potential of CNM-Au8, a novel drug compound aimed at improving mitochondrial health and protecting neuronal function in patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The results, presented at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, demonstrate encouraging outcomes, including reductions in biomarker plasma neurofilament light (NfL) levels and improved survival rates.
Multiple Sclerosis Findings:The clinical outcomes of the VISIONARY-MS Trial long-term open label extension (LTE) were shared during the ACTRIMS Forum. The trial focused on participants with stable relapsing multiple sclerosis (RMS) and provided nearly three years of follow-up data. The results showcased the favorable effects of CNM-Au8 treatment in improving disease progression and mitigating relapses in these patients. The compound showed promise in enhancing mitochondrial health and protecting neuronal function, suggesting its potential as a therapeutic option for MS.
Amyotrophic Lateral Sclerosis Findings:Additionally, Clene reported new data from the 12-month long-term open label extension (OLE) of the CNM-Au8 treatment arm in the HEALEY ALS Platform Trial. The findings indicated a reduction in biomarker plasma neurofilament light (NfL) levels, which is associated with disease progression and nerve cell damage in ALS patients. The data also highlighted improved survival rates in individuals receiving CNM-Au8 treatment. These results shed light on the therapeutic potential of CNM-Au8 in protecting neuronal function and potentially slowing the progression of ALS.
Conclusion:The clinical results presented by Clene Inc. demonstrate the potential of CNM-Au8, a novel drug compound, in improving mitochondrial health and protecting neuronal function in patients with both multiple sclerosis and amyotrophic lateral sclerosis. The findings showed promising outcomes, including reductions in biomarker plasma neurofilament light levels and improved survival rates. These results pave the way for further research and development of CNM-Au8 as a potential treatment option for neurodegenerative diseases.
Comments